Global Cancer Tumor Profiling Market

Cancer Tumor Profiling Market Size, Share, Growth Analysis, By Technology(Breast cancer, Lung cancer, Colorectal cancer), By Cancer type(genomic biomarker, protein biomarker), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35G2114 | Region: Global | Published Date: March, 2024
Pages: 219 |Tables: 62 |Figures: 78

Cancer Tumor Profiling Market Insights

Global Cancer Tumor Profiling Market size was valued at USD 10.73 billion in 2022 and is poised to grow from USD 11.87 billion in 2023 to USD 26.57 billion by 2031, at a CAGR of 10.6% during the forecast period (2024-2031).

The growth of cancer around the world and the use of biomarkers in tumor profiling are the primary factors driving the market for cancer detection and treatment products. The increase in cancer research and funding initiatives and technological advancements has led to the growth of the cancer/tumor profiling market. The growth of personalized medicine and point-of-care diagnostics is forecast to offer significant opportunities for market players during the next few years.

The cancer/tumor profiling market is not expected to be significantly impacted by the COVID-19 pandemic in 2020-2021. The COVID-19 outbreak has caused a significant decrease in cancer testing and diagnosis due to measures taken to protect against the virus. During the forecast period the cancer/tumor profiling market is including into genomics, proteomics, epigenetics, and metabolomics, Out of these, genomics is forecast to have the highest CAGR (19.7%) . The technique is used for the characterization of genes; it determines whether a gene in the complete genome is normal or abnormal. Mutations are responsible for the abnormal development of genes, which can help cancer cells survive. Cancer tumor profiling is a potential procedure for detecting and further studying cancer to identify changes in tumor stage, metabolism, and morphology.

US Cancer Tumor Profiling Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 10.73 billion

Largest Segment

genomic biomarker

Fastest Growth

protein biomarker

Growth Rate

10.6% CAGR

Global Cancer Tumor Profiling Market 2021-2030 ($ Bn)
Country Share for North America Region- 2021 (%)

To get more reports on the above market click here to Buy The Report

Cancer Tumor Profiling Market Segmental Analysis

The cancer tumor profiling market is segmented on the basis of By technology, by cancer type, by Biomarker and by application. Whereas , by technology is segmented into the Immunoassays, Next generation sequencing, Polymerase chain reaction, Mass Spectrometry, In-Situ hybridization, Microarrays and others.By cancer type is segmented into the Breast cancer, Lung cancer , Colorectal cancer, Prostate cancer, Melanoma cancer, and others. Biomarker is segmented into the genomic biomarker, protein biomarker. By application is segmented into the Research, biomarker discovery. By region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and MEA.

Cancer Tumor Profiling Market Analysis by Technology

Based on the technology, the immunoassays segment accounted for the largest market share in 2021. These tests are used as a standard to conduct tumor profiling on a large scale, helping measure the presence and concentration of analytes in a sample.  These tests are used for cancer diagnosis, prognosis, and treatment decisions. The tests used in clinical settings can help shorten hospital stays and decrease the severity of illnesses by identifying and assessing the progression of the disease. This information can then lead to improved therapeutic choices.

Analysis by Cancer

Based on the cancer type, the breast cancer segment accounted for the largest share of the cancer/tumor profiling market, ensured by lung cancer. Breast cancer is the major factor contributing to the large share of the cancer tumor profiling market. The lung cancer segment is expected to reach its highest level during the forecast period. The increasing incidence of lung cancer worldwide is helping to support the growth of this segment.

Cancer Tumor Profiling Market Analysis by Biomarker

Based on the biomarker type, The large share of genomic biomarker is due to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process. The protein biomarkers segment is estimated to grow at a high rate over the next few years as more researchers adopt proteomic methods for biomarker research. This will help speed up drug development processes.

Global Cancer Tumor Profiling Market By biomarker 2021 (%), 2023 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Cancer Tumor Profiling Market Regional Insights

North America is estimated to account for the largest share in terms of revenue owing to the presence of major players and rapid advances in technology. The high prevalence of cancer and the increasing research in oncology will lead to increased market growth in the treatment of cancer. The large share of the regional market for these diagnostic kits is due in large part to the quick uptake of advanced technologies by the firms manufacturing these kits.

Asia Pacific is a lucrative region, with expected steady growth over the next few years due to its large untapped markets and population pool.

Global Cancer Tumor Profiling Market By Geography, 2021-2030, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Cancer Tumor Profiling Market Dynamics

Cancer Tumor Profiling Market Drivers

Increasing Incidences of Cancer to Bolster Market Growth

  • Increase in cancer incidences is one of the major contributors to market growth in the complete cancer/tumor profiling market. the increasing burden of cancer can be attributed to various factors, Cancer is a complex and widespread disease, caused by a variety of factors. Population growth and aging, as well as the changing prevalence of certain causes of cancer, are all contributors to its prevalence.

Cancer Tumor Profiling Market Restraints

Technical Issues might Hinder Market Growth

  • Technical issues in sample collection and storage in the cancer /tumor profiling market are hindering market growth. Personalized medicine is a growing field in healthcare that is changing the way many diseases are identified, classified, and treated. This approach is being adopted by mainstream clinical practice, and it is already having a significant impact on the way diseases are treated. Recent advances in cancer treatment are particularly apparent in the area of oncology. Risks related to them can hinder market growth.

Request Free Customization of this report to help us to meet your business objectives.

Cancer Tumor Profiling Market Competitive Landscape

The market for cancer/tumor profiling products is growing, with new companies coming up with new ways to make money. MDNA Life Sciences Inc. launched its liquid biopsy Prostate Mitomic Test in May 2017 in the United States. Together with Helomics Corp., this test is designed to help doctors diagnose prostate cancer. The test uses the unique genetic characteristics of mitochondrial DNA, and it is exclusively available at Helomics’ clinical laboratories. In April 2017, Helomics Corporation also launched its Dynamic Clinical Health Insight Platform (D-CHIP), which can be used to study the detailed information related to cancer patients’ genomes, proteins, DNA, and RNA in order to identify more-effective biomarkers for pharmaceutical and diagnostic companies.

Cancer Tumor Profiling Market Top players company profiles

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN N.V.
  • F. Hoffmann-La Roche AG
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Personal Genome Diagnostics Inc.
  • Foundation Medicine, Inc.
  • Guardant Health, Inc.
  • NanoString Technologies, Inc.
  • Genomic Health, Inc.
  • Adaptive Biotechnologies Corporation
  • Caris Life Sciences
  • Becton, Dickinson and Company
  • PerkinElmer, Inc.
  • Natera, Inc.
  • Oxford Nanopore Technologies
  • Biocartis Group NV
  • ArcherDX, Inc.
  • Sysmex Corporation

Cancer Tumor Profiling Market Recent Developments

  • Haystack Oncology Inc. was purchased by US-based medical laboratory Quest Diagnostics in June 2023 for a sum of $450 million. With this acquisition, Quest Diagnostics hopes to improve research and development* capabilities, boost market share in cancer diagnostics, and broaden access to liquid biopsy technologies. An early-stage cancer company in the US is called Haystack Oncology Inc.
  • Thermo Fisher Scientific introduced the "Oncomine Dx Express Test" and "Oncomine Reporter Dx" with the "Ion Torrent Dx System" in September 2022. These CE-IVD (IVDD) tests are intended for use in clinical labs to provide clinically relevant biomarker results in a single day and to increase the company's access to precision oncology biomarker testing.
  • To market its range of genetic tests, Avesthagen Limited and Wipro Limited signed a four-year strategic collaboration in June 2022. Genome panels, which provide extremely specialized, disease-centric analysis for ailments like cancer, autoimmune disorders, neurodegenerative diseases, and uncommon disease situations, are part of the portfolio.

Cancer Tumor Profiling Key Market Trends

  • The trends in the cancer/tumor profiling market is the Integration of omics data and advances in liquid biopsy tests is expected to grow at the highest CAGR during the forecast period. Personalized medicine is a growing field of healthcare research that is changing the way diseases are identified, classified, and treated. It has now become mainstream clinical practice, and is being used to treat many different diseases. The advances in cancer care are particularly apparent in the area of oncology.

Cancer Tumor Profiling Market SkyQuest Analysis

Sky Quest’s ABIRAW (Advanced Business Intelligence, Research and Analysis Wing) is our Business Information Services team that collects, collates, Co-relates and analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

According to our Global Cancer Tumor Profiling Market analysis, Increasing investment in research & development, particularly in developed and developing nations, will further open up attractive market expansion potential for medical instruments and technologies. The market growth rate is also being supported by research and development efforts being made to improve the whole process of cancer detection and treatment as well as to integrate cutting-edge technologies into healthcare facilities.

Report Metric Details
Market size value in 2023 USD 10.73 billion
Market size value in 2031 USD 26.57 billion
Growth Rate 10.6%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Technology
    • Breast cancer, Lung cancer, Colorectal cancer
  • Cancer type
    • genomic biomarker, protein biomarker
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN N.V.
  • F. Hoffmann-La Roche AG
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Personal Genome Diagnostics Inc.
  • Foundation Medicine, Inc.
  • Guardant Health, Inc.
  • NanoString Technologies, Inc.
  • Genomic Health, Inc.
  • Adaptive Biotechnologies Corporation
  • Caris Life Sciences
  • Becton, Dickinson and Company
  • PerkinElmer, Inc.
  • Natera, Inc.
  • Oxford Nanopore Technologies
  • Biocartis Group NV
  • ArcherDX, Inc.
  • Sysmex Corporation

Cancer Tumor Profiling Market Recent Developments

  • Haystack Oncology Inc. was purchased by US-based medical laboratory Quest Diagnostics in June 2023 for a sum of $450 million. With this acquisition, Quest Diagnostics hopes to improve research and development* capabilities, boost market share in cancer diagnostics, and broaden access to liquid biopsy technologies. An early-stage cancer company in the US is called Haystack Oncology Inc.
  • Thermo Fisher Scientific introduced the "Oncomine Dx Express Test" and "Oncomine Reporter Dx" with the "Ion Torrent Dx System" in September 2022. These CE-IVD (IVDD) tests are intended for use in clinical labs to provide clinically relevant biomarker results in a single day and to increase the company's access to precision oncology biomarker testing.
  • To market its range of genetic tests, Avesthagen Limited and Wipro Limited signed a four-year strategic collaboration in June 2022. Genome panels, which provide extremely specialized, disease-centric analysis for ailments like cancer, autoimmune disorders, neurodegenerative diseases, and uncommon disease situations, are part of the portfolio.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Cancer Tumor Profiling Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Cancer Tumor Profiling Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Cancer Tumor Profiling Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Tumor Profiling Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Tumor Profiling Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Cancer Tumor Profiling Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cancer Tumor Profiling Market size was valued at USD 10.73 billion in 2022 and is poised to grow from USD 11.87 billion in 2023 to USD 26.57 billion by 2031, at a CAGR of 10.6% during the forecast period (2024-2031).

The market for cancer/tumor profiling products is growing, with new companies coming up with new ways to make money. MDNA Life Sciences Inc. launched its liquid biopsy Prostate Mitomic Test in May 2017 in the United States. Together with Helomics Corp., this test is designed to help doctors diagnose prostate cancer. The test uses the unique genetic characteristics of mitochondrial DNA, and it is exclusively available at Helomics’ clinical laboratories. In April 2017, Helomics Corporation also launched its Dynamic Clinical Health Insight Platform (D-CHIP), which can be used to study the detailed information related to cancer patients’ genomes, proteins, DNA, and RNA in order to identify more-effective biomarkers for pharmaceutical and diagnostic companies. 'Illumina, Inc.', 'Thermo Fisher Scientific, Inc.', 'QIAGEN N.V.', 'F. Hoffmann-La Roche AG', 'Agilent Technologies, Inc.', 'Myriad Genetics, Inc.', 'Personal Genome Diagnostics Inc.', 'Foundation Medicine, Inc.', 'Guardant Health, Inc.', 'NanoString Technologies, Inc.', 'Genomic Health, Inc.', 'Adaptive Biotechnologies Corporation', 'Caris Life Sciences', 'Becton, Dickinson and Company', 'PerkinElmer, Inc.', 'Natera, Inc.', 'Oxford Nanopore Technologies', 'Biocartis Group NV', 'ArcherDX, Inc.', 'Sysmex Corporation', 'Haystack Oncology Inc. was purchased by US-based medical laboratory Quest Diagnostics in June 2023 for a sum of $450 million. With this acquisition, Quest Diagnostics hopes to improve research and development* capabilities, boost market share in cancer diagnostics, and broaden access to liquid biopsy technologies. An early-stage cancer company in the US is called Haystack Oncology Inc.', 'Thermo Fisher Scientific introduced the "Oncomine Dx Express Test" and "Oncomine Reporter Dx" with the "Ion Torrent Dx System" in September 2022. These CE-IVD (IVDD) tests are intended for use in clinical labs to provide clinically relevant biomarker results in a single day and to increase the company's access to precision oncology biomarker testing.', 'To market its range of genetic tests, Avesthagen Limited and Wipro Limited signed a four-year strategic collaboration in June 2022. Genome panels, which provide extremely specialized, disease-centric analysis for ailments like cancer, autoimmune disorders, neurodegenerative diseases, and uncommon disease situations, are part of the portfolio.'

Increase in cancer incidences is one of the major contributors to market growth in the complete cancer/tumor profiling market. the increasing burden of cancer can be attributed to various factors, Cancer is a complex and widespread disease, caused by a variety of factors. Population growth and aging, as well as the changing prevalence of certain causes of cancer, are all contributors to its prevalence.

The trends in the cancer/tumor profiling market is the Integration of omics data and advances in liquid biopsy tests is expected to grow at the highest CAGR during the forecast period. Personalized medicine is a growing field of healthcare research that is changing the way diseases are identified, classified, and treated. It has now become mainstream clinical practice, and is being used to treat many different diseases. The advances in cancer care are particularly apparent in the area of oncology.

North America is estimated to account for the largest share in terms of revenue owing to the presence of major players and rapid advances in technology. The high prevalence of cancer and the increasing research in oncology will lead to increased market growth in the treatment of cancer. The large share of the regional market for these diagnostic kits is due in large part to the quick uptake of advanced technologies by the firms manufacturing these kits.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cancer Tumor Profiling Market

Product ID: SQMIG35G2114

$5,300
BUY NOW GET FREE SAMPLE